Scholarlink

Background <p>Adequate triage of patients with symptoms suggestive of ACS is crucial. Considering who calls might be useful to improve telephone triage of these patients. In this article, we aim to assess whether a call made by a surrogate is related to urgency allocation or higher odds of an acute coronary syndrome (ACS) than patient-initiated calls, and to assess possible gender differences.</p> Methods <p>Cross-sectional study of patients with symptoms suggestive of ACS who called the out-of-hours service in primary care (OHS-PC). Calls were classified into “patient-initiated call” or “surrogate call”. Call and patient characteristics were collected. Odds ratios (OR) were calculated for the relationship between the type of call and (i) urgency allocation, (ii) ACS, and (iii) ACS or other life-threatening event, stratified for gender.</p> Results <p>In total 2,428 recordings were included for analysis. Around half of the recordings were surrogate calls, and these more often received a high urgency (80.0%) than patient-initiated calls (57.8%), OR 2.92 (95%CI 2.44–3.50); in women OR 3.46, (95%CI 2.70–4.45), in men OR 2.42 (95%CI 1.86–3.16). Of all participants, 11.0% were diagnosed with an ACS; in women 8.0%, in men 14.7%. In the surrogate call group this was 14.4%, in the patient-initiated call group 7.6%; OR 2.04 (95%CI 1.57–2.67). In women, the OR was 2.46 (95%CI 1.63–3.77), in men 1.69 (95%CI 1.20–2.41).</p> Conclusions <p>Compared to patients who call themselves, surrogate calls on behalf of a patient with symptoms suggestive of ACS receive more often a high urgency, and these patients have a risk twice as high of an ACS, an effect similar in women and men. It is useful for triage at the OHS-PC to consider who calls if it concerns a patient with symptoms suggestive of ACS.</p> Clinical trial number <p>NTR7331. Registration Date 26-06-2018.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnosing acute coronary syndrome in telephone triage: does it matter who initially calls? A cross-sectional study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月14日

查看全文
  • Mathé Delissen,
  • Anique SM Dobbe,
  • Daphne CA Erkelens,
  • Loes TC Wouters,
  • Hester M den Ruijter,
  • Joy SA Corsel,
  • Alja Sluiter,
  • Frans H Rutten,
  • Dorien LM Zwart

摘要

Background

Adequate triage of patients with symptoms suggestive of ACS is crucial. Considering who calls might be useful to improve telephone triage of these patients. In this article, we aim to assess whether a call made by a surrogate is related to urgency allocation or higher odds of an acute coronary syndrome (ACS) than patient-initiated calls, and to assess possible gender differences.

Methods

Cross-sectional study of patients with symptoms suggestive of ACS who called the out-of-hours service in primary care (OHS-PC). Calls were classified into “patient-initiated call” or “surrogate call”. Call and patient characteristics were collected. Odds ratios (OR) were calculated for the relationship between the type of call and (i) urgency allocation, (ii) ACS, and (iii) ACS or other life-threatening event, stratified for gender.

Results

In total 2,428 recordings were included for analysis. Around half of the recordings were surrogate calls, and these more often received a high urgency (80.0%) than patient-initiated calls (57.8%), OR 2.92 (95%CI 2.44–3.50); in women OR 3.46, (95%CI 2.70–4.45), in men OR 2.42 (95%CI 1.86–3.16). Of all participants, 11.0% were diagnosed with an ACS; in women 8.0%, in men 14.7%. In the surrogate call group this was 14.4%, in the patient-initiated call group 7.6%; OR 2.04 (95%CI 1.57–2.67). In women, the OR was 2.46 (95%CI 1.63–3.77), in men 1.69 (95%CI 1.20–2.41).

Conclusions

Compared to patients who call themselves, surrogate calls on behalf of a patient with symptoms suggestive of ACS receive more often a high urgency, and these patients have a risk twice as high of an ACS, an effect similar in women and men. It is useful for triage at the OHS-PC to consider who calls if it concerns a patient with symptoms suggestive of ACS.

Clinical trial number

NTR7331. Registration Date 26-06-2018.